How to harness Tuberculosis bacteria in the fight against respiratory disease.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How to harness Tuberculosis bacteria in the fight against respiratory disease.
Released on: February 26, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Over millennia, microorganisms such as Tuberculosis have evolved ways to ensure the survival of their hosts by manipulating the immune system.
  • Summary
  • Transcript
  • Participants
  • Company
Over millennia, microorganisms such as Tuberculosis have evolved ways to ensure the survival of their hosts by manipulating the immune system. Andrew Lightfoot, CEO of Peptinnovate, reveals the concept and IP behind their unique peptide treatment for allergies and asthma.
Over millennia, microorganisms such as Tuberculosis have evolved ways to ensure the survival of their hosts by manipulating the immune system. Andrew Lightfoot, CEO of Peptinnovate, reveals the concept and IP behind their unique peptide treatment for allergies and asthma.
Andrew has an extensive career of leading successful drug discovery and development opportunities and founded Peptinnovate in 2011. Andrew is medicinal chemist by background and has 17 years’ experience in leading successful small molecule and peptide drug discovery initiatives in multiple therapeutic areas, including antibiotics, neurosciences and immuno-inflammation. His career spans both large pharma and since 2010, biotech companies. At GSK, he led discovery efforts leading to a number of successful drug candidates for development. From 2010-11 he was Chief Executive Officer of Helperby Therapeutics where he helped design and successfully execute a Phase 2a clinical study in eradication of nasal MRSA. From 2012-14, he was Non-Executive Director of CytaCoat AB, a Swedish antimicrobial coating company.
Peptinnovate
Peptinnovate is a specialty biopharmaceutical company that is discovering and developing new treatments for respiratory disease. Peptinnovate is founded on the principle that mycobacterium tuberculosis (mTB) through co-evolution with man can modify the human immune system. A number of publications have merged in which there is a clear reduction in asthma and allergy amongst those individuals infected with mTB across the globe. mTB has developed mechanisms in which the allergic and asthma phenotype can be reduced. Peptinnovate has identified molecules derived from mTB that appear to have the desired immuno-modulating effects in preclinical models and have optimised molecules to proprietary drug candidates. Peptinnovate is focused on discovering, developing and commercialising a range of therapies for the treatment of respiratory diseases and other debilitating inflammatory disorders.